

Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor

Test ID: NONCP

Explanation:

On the effective date, NONCP: Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor will be updated to include changes to the DNA subpanel to better align with current World Health Organization classification guidelines; 27 genes will be added and 57 will be removed. Microsatellite stability status will be provided and tissue requirements will be updated.

Please reference the [Mayo Clinic Laboratories website](#) to review associated Targeted DNA Gene Regions Interrogated by Neuro-Oncology Panel for specific gene region information.

Gene Additions: *CYSLTR2, DGCR8, DICER1, DROSHA, EED, EIF1AX, ERBB2, H3-3B, H3C14, HRAS, KBTBD4, KIT, MET, MTOR, NTRK1, NTRK2, NTRK3, PBRM1, PLCB4, PMS2, POLD1, PRKCA, SF3B1, SMARCA2, SMARCA1, SUZ12, VHL.*

Gene Removals: *AKT2, AKT3, ARID2, ATM, BCORL1, CBL, CDK6, CDKN2C, CHEK2, CTDNEP1, DNMT3A, EZH2, GLI2, GLI3, GPS2, JAK2, KDM5A, KDM5C, KMT2B, KMT2C, KMT2D, LDB1, LRP1B, MDM2, MSH3, MYB, MYBL1, MYC, MYCN, NOTCH2, PARP1, PIK3C2B, PIK3R2, POT1, PTCH2, PTPRD, QKI, RAF1, RELA, RPL5, SDHA, SDHB, SDHC, SDHD, SHH, SHOC2, SOS1, STAG2, STAT3, TET1, TET2, TPTE2, WRN, WT1, YAP1, ZBTB20.*

Current Specimen Required
30% tumor is required for this assay

New Specimen Required
20% tumor is required for this assay

Questions

Contact Michelle Rath, Laboratory Resource Coordinator at 800-533-1710.